

Preplanned Studies

Impact of Whole Lung Lavage on Pneumoconiosis Patients — China, 2018–2022

Yun Chen¹; Xiangpei Lyu¹; Tao Li¹; Huanqiang Wang^{1,†}

Summary

What is already known about this topic?

The application of whole lung lavage (WLL) for the clinical treatment of pneumoconiosis is prevalent in China. Several scholars have reported success in the treatment of early-stage pneumoconiosis. Nonetheless, the overall efficacy of WLL in the management of pneumoconiosis remains ambiguous.

What is added by this report?

The preliminary evaluation of the effects of WLL on pneumoconiosis patients was conducted using follow-up data from 2020 to 2022, after controlling for confounding factors via propensity score matching. While the study found that WLL may improve some pneumoconiosis symptoms, no significant enhancements were observed in overall health status or quality of life.

What are the implications for public health practice?

The findings of this research indicate limited efficacy of WLL in treating patients with pneumoconiosis, thereby suggesting that it should not be utilized as a standard treatment procedure for this condition.

Whole lung lavage (WLL) is a surgical procedure utilized in China to treat pneumoconiosis, despite the scholarly debate surrounding its efficacy. The National Institute for Occupational Health and Poisoning Control, part of the Chinese Center for Disease Control and Prevention (China CDC), conducted a comprehensive study on pneumoconiosis patients' health-seeking behaviors across 27 provincial-level administrative divisions (PLADs) over a three-year period, from January 2018 to December 2020. Utilizing baseline data, follow-up patient information, and WLL-related data, a retrospective cohort study was undertaken to evaluate WLL's impact and gauge the changes in pneumoconiosis-related symptoms and patient quality of life. The study, empowered by propensity score matching (PSM), contrasted 514 patients in both the control and lavage groups. The

data illustrated that the patients in the lavage group displayed a marked improvement in expectoration symptoms and self-care than those in the control group. However, this study suggests that while WLL can alleviate some pneumoconiosis symptoms, it offers no significant enhancement to a patient's overall health status or quality of life.

The present study utilized data from a survey on health-seeking behaviors and a subsequent follow-up survey of pneumoconiosis patients across 27 PLADs in China. The investigation was conducted by the National Institute for Occupational Health and Poisoning Control, affiliated with China CDC (*1*).

The initial health-seeking behavior survey, undertaken from January 2018 to December 2020, involved studying 9,934 pneumoconiosis patients. Of these, 8,198 valid questionnaires were collected, resulting in a questionnaire recovery rate of 82.5%.

The research group subsequently executed a second telephone follow-up survey from 2020 to 2022. This included the 8,198 pneumoconiosis patients from the initial survey. As of November 2022, follow-up communication had been completed with 5,561 patients. However, the remaining 2,637 patients, who were still being followed up, were not included in the current study due to timing constraints.

The follow-up survey amassed a total of 4,644 valid questionnaires, yielding a questionnaire recovery rate of 83.5%. Tragically, the survey revealed that 232 pneumoconiosis patients passed away during the second follow-up.

The current study finally selected 514 cases, both from the control group (those who had not received WLL treatment prior to the first survey) and the lavage group (those who had received WLL treatment prior to the first survey). A PSM technique was used to match the baseline data from the first survey of 4,412 surviving pneumoconiosis patients with valid questionnaires; 3,322 did not receive WLL before the first survey, and 1,090 received WLL before the first survey (*Figure 1*).

This study utilized PSM to create control and lavage




FIGURE 1. Flowchart of enrolled patients.
Abbreviation: PSM=propensity score matching.

groups from the pool of surveyed pneumoconiosis patients in each medical institution. The final control and lavage groups each included 514 patients. Factors used for matching consisted of gender, age, body mass index (BMI), patients' source, annual family income, pneumoconiosis stage and type, presence of tuberculosis, self-reported health status, medications for pneumoconiosis, oxygen therapy, and practice of breathing exercises, all of which are crucial influencers on pneumoconiosis patients' decision to undergo WLL and their overall health condition. The Nearest Neighbor Matching method was applied in a 1:1 matching ratio with a caliper value of 0.01. The basic information of the two groups of patients is shown in [Supplementary Tables S1–S2](https://weekly.chinacdc.cn/) (available in <https://weekly.chinacdc.cn/>). The study referenced the European EQ-5D-3L scale to describe patient quality of life. To compare pneumoconiosis-related symptoms and quality of life differences between the two groups, the *t*-test, chi-squared test or Fisher's exact probability method was implemented, while paired *t*-test and paired chi-squared test were used to assess differences between initial and follow-up surveys for both groups. All analyses used SPSS software (version 26.0, SPSS Inc, Chicago, IL, USA). The accepted statistically significant level was set at 0.05 (two-tailed). Ethical approval for this research was granted by the Ethics Committee of the National Institute for Occupational Health and Poison Control, China CDC (Approval No: 201720). Written informed consent was obtained from all participants.

Following PSM, a total of 514 patients were found in each of the control group and the lavage group. The average age in both groups was found to be 53.3 years, with a standard deviation of 9.7 and 8.3, respectively, a difference which was not considered statistically significant ($t=-0.052$, $P=0.959$). The average interval between the two surveys was found to be

approximately 1.9 years in both groups, with a standard deviation of 0.9 and 0.8, respectively, revealing no significant statistical difference ($t=0.799$, $P=0.424$).

In the initial survey, a notable statistical difference was detected regarding expectoration symptoms between the two groups ($P<0.001$). The percentage of patients exhibiting no expectoration was lower in the lavage group than in the control group (11.7% *vs.* 19.8%). Conversely, the patient percentage with minimal expectoration was higher than in the control group (62.8% *vs.* 54.5%). However, in the subsequent follow-up survey, no meaningful difference in expectoration symptoms was found between the groups ($P=0.606$) (Table 1).

A comparative analysis of pneumoconiosis symptoms before and after the initial and follow-up surveys indicates a significant statistical variation in the severity of the identified eight symptoms across the two groups ($P<0.05$). We noted a reduction in the proportion of patients in the highest severity level of each symptom and conversely, observed an increased proportion of patients without the said symptoms in both groups ([Supplementary Table S3](https://weekly.chinacdc.cn/), available in <https://weekly.chinacdc.cn/>).

The initial and subsequent surveys did not reveal any statistically significant disparities in the five elements of self-reported quality of life and health status among pneumoconiosis patients across both groups ($P>0.05$) ([Supplementary Table S4](https://weekly.chinacdc.cn/), available in <https://weekly.chinacdc.cn/>).

Upon comparing the quality of life before and after initial and follow-up surveys, no statistically significant changes were observed in the self-care of pneumoconiosis patients from the control group ($P=0.083$). Conversely, the differences within the lavage group were statistically significant ($P<0.001$), exemplified by an increased proportion of patients

TABLE 1. Comparison of pneumoconiosis-related symptoms between the control group and the lavage group — China, 2018–2022 (*n*=514).

Symptoms	The first survey				Secondary follow-up survey			
	Control group <i>n</i> (%)	Lavage group <i>n</i> (%)	χ^2	<i>P</i>	Control group <i>n</i> (%)	Lavage group <i>n</i> (%)	χ^2	<i>P</i>
Cough			2.079	0.354			4.265	0.119
No	51 (9.9)	38 (7.4)			113 (22.0)	135 (26.3)		
Mild	310 (60.3)	319 (62.1)			313 (60.9)	310 (60.3)		
Moderate and severe	153 (29.8)	157 (30.5)			88 (17.1)	69 (13.4)		
Expectoration			13.959	<0.001			1.003	0.606
No	102 (19.8)	60 (11.7)			166 (32.3)	181 (35.2)		
Mild	280 (54.5)	323 (62.8)			270 (52.5)	260 (50.6)		
Moderate and severe	132 (25.7)	131 (25.5)			78 (15.2)	73 (14.2)		
Chest tightness			2.661	0.264			0.255	0.880
No	64 (12.5)	48 (9.3)			164 (31.9)	157 (30.5)		
Mild	295 (57.4)	310 (60.3)			258 (50.2)	261 (50.8)		
Moderate and severe	155 (30.2)	156 (30.4)			92 (17.9)	96 (18.7)		
Chest pain			5.736	0.057			4.578	0.101
No	199 (38.7)	170 (33.1)			336 (65.4)	329 (64.0)		
Mild	197 (38.3)	234 (45.5)			118 (23.0)	141 (27.4)		
Moderate and severe	118 (23.0)	110 (21.4)			60 (11.7)	44 (8.6)		
Dyspnea			0.439	0.803			4.370	0.112
No	131 (25.5)	129 (25.1)			176 (34.2)	208 (40.5)		
Mild	222 (43.2)	232 (45.1)			230 (44.7)	212 (41.2)		
Moderate and severe	161 (31.3)	153 (29.8)			108 (21.0)	94 (18.3)		
Hemoptysis			0.957	0.328			0.324	0.569
No	460 (89.5)	450 (87.5)			486 (94.6)	490 (95.3)		
Yes	54 (10.5)	64 (12.5)			28 (5.4)	24 (4.7)		

Note: The categories for cough severity include mild (intermittent cough not affecting daily activities), moderate, and severe (frequent or violent cough disrupting daily activities and rest). Expectoration is categorized as mild (sputum volume of 10–50 mL during day and night), moderate, and severe (sputum volume exceeding 50 mL during day and night). Chest tightness ranges from mild (intermittent discomfort) to moderate and severe (persistent tightness restricting breathing). Chest pain and dyspnea are classified as mild (occurs during physical activities), moderate, and severe (manifests during daily activities and rest).

reported to have “no problem” in terms of self-care (Table 2). The average variation in self-reported health status between the two surveys was 9.6±16.7 in the control group and 10.3±18.5 in the lavage group. This difference, however, did not reach statistical significance ($t=-0.678$, $P=0.498$).

DISCUSSION

This research involved the selection of lavage and control groups through PSM for the purpose of comparing differences in pneumoconiosis-related symptoms and quality of life. These two groups of pneumoconiosis patients exhibited similar baseline characteristics, allowing for a preliminary evaluation of the effects of WLL on these patients. The intent was to stimulate thought and inform future empirical studies

focusing on the long-term efficacy of WLL for pneumoconiosis patients. The Consensus of Chinese Experts on Pneumoconiosis Treatment (2018) purports that while WLL significantly improves clinical symptoms in the short term, current evidence does not substantiate a marked therapeutic impact on lung function and pulmonary fibrosis. As WLL is an invasive treatment, it is currently not upheld as a standard treatment for pneumoconiosis (2). The results from the study’s initial survey are presented herewith.

The survey data revealed a 17.8% prevalence rate for WLL use among participants, signaling its considerable utilization as a nonstandard treatment technique. Earlier studies typically gauged the efficacy of WLL via self-regulated pre-and post-surgical evaluations, concluding that WLL might have a positive impact on alleviating short-term pneumoconiosis symptoms

TABLE 2. Comparative analysis of quality-of-life differences between the two patient groups across two surveys — China, 2018–2022 (*n*=514).

Quality of life	Group	Level	The first survey	Secondary follow-up survey	<i>P</i>
Mobility, <i>n</i> (%)	Control group	No problems	302 (58.8)	365 (71.0)	<0.001
		Moderate problems	206 (40.1)	140 (27.2)	
		Extreme problems	6 (1.2)	9 (1.8)	
	Lavage group	No problems	322 (62.6)	388 (75.5)	<0.001
		Moderate problems	189 (36.8)	123 (23.9)	
		Extreme problems	3 (0.6)	3 (0.6)	
Self-care, <i>n</i> (%)	Control group	No problems	405 (78.8)	426 (82.9)	0.083
		Moderate problems	106 (20.6)	82 (16.0)	
		Extreme problems	3 (0.6)	6 (1.2)	
	Lavage group	No problems	386 (75.1)	442 (86.0)	<0.001
		Moderate problems	125 (24.3)	70 (13.6)	
		Extreme problems	3 (0.6)	2 (0.4)	
Usual activities, <i>n</i> (%)	Control group	No problems	251 (48.8)	317 (61.7)	<0.001
		Moderate problems	232 (45.1)	173 (33.7)	
		Extreme problems	31 (6.0)	24 (4.7)	
	Lavage group	No problems	264 (51.4)	349 (67.9)	<0.001
		Moderate problems	221 (43.0)	143 (27.8)	
		Extreme problems	29 (5.6)	22 (4.3)	
Pain/discomfort, <i>n</i> (%)	Control group	No problems	118 (23.0)	233 (45.3)	<0.001
		Moderate problems	352 (68.5)	255 (49.6)	
		Extreme problems	44 (8.6)	26 (5.1)	
	Lavage group	No problems	147 (28.6)	234 (45.5)	<0.001
		Moderate problems	330 (64.2)	268 (52.1)	
		Extreme problems	37 (7.2)	12 (2.3)	
Anxiety/depression, <i>n</i> (%)	Control group	No problems	219 (42.6)	292 (56.8)	<0.001
		Moderate problems	214 (41.6)	193 (37.5)	
		Extreme problems	81 (15.8)	29 (5.6)	
	Lavage group	No problems	217 (42.2)	313 (60.9)	<0.001
		Moderate problems	210 (40.9)	176 (34.2)	
		Extreme problems	87 (16.9)	25 (4.9)	
Health status self-score ($\bar{x} \pm s$)	Control group	/	59.1±17.3	68.7±15.8	<0.001
	Lavage group	/	59.0±17.2	69.3±16.3	<0.001

Note: “/” means health status self-score did not differentiate levels.

(3–4). Nonetheless, the present research suggests that both patient groups exhibited improved health status. This improvement may be attributable to recent enhancements in national support policies for individuals with pneumoconiosis and the survivor effect (5–6). Therefore, when assessing WLL’s impact on pneumoconiosis patients, mere self-comparisons before and after the treatment may not accurately reflect the reality of their condition.

In studies involving control groups, the influential confounding factors affecting the health condition of patients with pneumoconiosis were either not adjusted

or only a few were accounted for. Despite this, these studies generally concluded that WLL had short-term beneficial effects on the patients’ health (7–8). Before adjusting for confounders, WLL was linked to improvements in numerous respiratory symptoms and quality of life. WLL typically targets patients with relatively mild conditions that are more likely to tolerate the procedure, introducing potential selection bias in the outcomes (9–10). In our study, however, we employed a large sample size and controlled for the principal factors that may influence both the patients’ decision to undergo WLL and their health conditions.

Using PSM, we equalized the baseline characteristics of both patient groups. This approach allowed us to evaluate the effects of WLL on pneumoconiosis patients more accurately.

The findings of the study indicate that WLL yielded a moderate effect on alleviating expectoration symptoms when juxtaposed with the control. However, there was no significant improvement in symptoms such as coughing, chest tightness, chest pain, and dyspnea in comparison to the control. This finding is consistent with the underlying mechanism that WLL works by cleansing the respiratory tract and pulmonary sputum of patients with pneumoconiosis, thus aiding those with substantial sputum stasis that is challenging to expectorate. In terms of quality of life assessment, WLL only significantly enhanced the self-care abilities of the pneumoconiosis patients contrasted with the control. However, no notable improvements were evident in the remaining four aspects and the overall health status compared with the control group.

This study indicates that WLL has a modest impact on pneumoconiosis patients and should not be considered a standard treatment. However, this research primarily assessed the influence of whole lung lavage based on patients' subjective experiences of symptoms and quality of life, without incorporating objective measurements, such as chest imaging and lung function. This omission represents a limitation. Future research on the use of WLL in pneumoconiosis treatment should endeavor to provide stronger evidence by choosing indicators that can objectively assess disease severity, progression, and patient quality of life. It should also account for potential confounding factors, such as the quality of WLL operation, patients' dust exposure history, medication therapies, and other treatment modalities. A systematic evaluation of WLL's long-term efficacy using standardized methodologies is recommended to fairly assess WLL's cost-effectiveness for pneumoconiosis patients.

The current study inadequately addresses the potential influence of varied WLL procedure quality across different medical institutions on patient outcomes. Furthermore, the research does not provide detailed information regarding the dust exposure history and work type of participants, likely influencing the assessed impact of WLL on pneumoconiosis patients. Additionally, potential disparities in data collection methods could introduce bias as the initial questionnaire involved face-to-face

interviews, whereas the secondary follow-up predominantly used telephone interviews. Consequently, the potential for information bias is apparent in the comparison of the two surveys' results.

Conflicts of interest: No conflicts of interest.

Acknowledgements: The participants in the study and the members of the survey teams in each of the 27 regional centers, and the project development and management teams.

Funding: Occupational population survey in key industries (102393220020090000017).

doi: [10.46234/ccdcw2023.160](https://doi.org/10.46234/ccdcw2023.160)

Corresponding author: Huanqiang Wang, wanghq@niohp.chinacdc.cn.

¹ National Institute of Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention, Beijing, China.

Submitted: July 02, 2023; Accepted: September 19, 2023

REFERENCES

1. Wang HQ, Dai HP, He JY, Lyu X, Zhang XR, Li T. Epidemiological characteristics of pulmonary tuberculosis in patients with pneumoconiosis based on its social determinants and risk factors in China: a cross-sectional study from 27 provinces. *Chin Med J (Engl)* 2022;135(24):2984 – 97. <http://dx.doi.org/10.1097/CM9.00000000000002486>.
2. Occupational Lung Disease Group of Labor Hygiene and Occupational Diseases Branch of Chinese Preventive Medicine Association. Consensus of Chinese experts on pneumoconiosis treatment (2018). *J Environ Occup Med* 2018;35(8):677 – 89. (In Chinese).
3. Gao W, Wu J, Qiu CW, Yang CM. Mid-term therapeutic effects of bilateral synchronous massive whole lung lavage on lung functions of 39 patients with coal worker's pneumoconiosis. *J Prev Med Inf* 2016;32(6):515 – 5. (In Chinese).
4. Sun ZP, Li BP, Gao LN, Ji YR, Zhou YZ, Hou BW, et al. Comparative analysis of quality of life in patients with pneumoconiosis before and after whole-lung large-volume lavage. *Occup Health* 2021;37(13):1834 – 9. (In Chinese).
5. The State Council. Opinions of the State Council on the implementation of the healthy China initiative [Internet]. China: The State Council. 2019. http://www.gov.cn/zhengce/content/2019-07/15/content_5409492.htm. [2023-6-16]. (In Chinese).
6. Ministry of Human Resources and Social Security, National Health Commission. Notice of the two departments on work-related injury insurance in key industries of pneumoconiosis [Internet]. China: Ministry of Human Resources and Social Security. 2019. http://www.gov.cn/fuwu/2019-12/10/content_5459923.htm. [2023-6-16]. (In Chinese).
7. Zhang YM, Zhang HT, Wang CY, Wang W, Wu J, Wang C. Long-term therapeutic effects of whole lung lavage in the management of silicosis. *Chin J Ind Hyg Occup Dis* 2012;30(9):690 – 3. (In Chinese).
8. Wu CL, Yu JX, Xie LS. meta analysis on the effects of the whole lung lavage in treating pneumoconiosis. *Occup Health Damage* 2019;34(5):273 – 9. (In Chinese).
9. Yi J, Wang SP. Clinical application and research progress of whole lung lavage. *Int J Respir* 2015;35(19):1517 – 20. (In Chinese).
10. Liu CP. Complications and life quality survey of 995 cases simultaneous large volume bilateral lungs lavage. *World Latest Med Inf* 2019;19(58):15 – 6,30. (In Chinese).

SUPPLEMENTARY MATERIALS

SUPPLEMENTARY TABLE S1. Comparison of demographic and sociological characteristics between control and lavage groups in pneumoconiosis patients ($n=514$).

Demographic and sociological characteristics	Control group, n (%)	Lavage group, n (%)	χ^2	P
Sex			0.609	0.435
Male	508 (98.8)	505 (98.2)		
Female	6 (1.2)	9 (1.8)		
Age, years			5.320	0.150
≤ 40	41 (8.0)	26 (5.1)		
41–50	169 (32.9)	166 (32.3)		
51–60	194 (37.7)	220 (42.8)		
> 60	110 (21.4)	102 (19.8)		
BMI			0.888	0.828
< 18.5	25 (4.9)	23 (4.5)		
18.5–23.9	248 (48.2)	239 (46.5)		
24–27.9	193 (37.5)	196 (38.1)		
≥ 28	48 (9.3)	56 (10.9)		
Marital status			3.772	0.438
Married	482 (93.8)	485 (94.4)		
Divorced	9 (1.8)	8 (1.6)		
Widowed	13 (2.5)	14 (2.7)		
Single	10 (1.9)	5 (1.0)		
Others	0 (0.0)	2 (0.4)		
Educational level			0.995	0.910
Illiterate or semiliterate	23 (4.5)	22 (4.3)		
Primary school	182 (35.4)	190 (37.0)		
Middle school	230 (44.7)	223 (43.4)		
High school or junior college or above	75 (14.6)	77 (15.0)		
Others	4 (0.8)	2 (0.4)		
District			/	1.000*
Eastern region	246 (47.9)	246 (47.9)		
Central region	98 (19.1)	98 (19.1)		
Western region	168 (32.7)	168 (32.7)		
Northeastern region	2 (0.4)	2 (0.4)		
Source of cases			5.780	0.123
Household investigation	46 (8.9)	59 (11.5)		
Outpatient	174 (33.9)	146 (28.4)		
Hospitalized	243 (47.3)	266 (51.8)		
Occupational health examination	51 (9.9)	43 (8.4)		

Note: “/” means Fisher exact probability method does not give chi-square values.

Abbreviation: BMI=body mass index.

* Fisher exact probability method was used for statistics.

SUPPLEMENTARY TABLE S2. Comparison of pneumoconiosis and complications between the control group and the lavage group ($n=514$).

Pneumoconiosis and complications	Control group, n (%)	Lavage group, n (%)	χ^2	P
Stage of pneumoconiosis			6.780	0.079
Stage I	247 (48.1)	218 (42.4)		
Stage II	112 (21.8)	146 (28.4)		
Stage III	115 (22.4)	116 (22.6)		
Unstaged clinical diagnosis	40 (7.8)	34 (6.6)		
Type of pneumoconiosis			0.017	0.992
Silicosis	238 (46.3)	238 (46.3)		
Coal worker's pneumoconiosis	242 (47.1)	243 (47.3)		
Others	34 (6.6)	33 (6.4)		
Complications				
PTB			0.275	0.600
No	481 (93.6)	485 (94.4)		
Yes	33 (6.4)	29 (5.6)		
Pulmonary heart disease			0.157	0.692
No	485 (94.4)	482 (93.8)		
Yes	29 (5.6)	32 (6.2)		
Pulmonary bullae or pneumothorax			0.285	0.594
No	463 (90.1)	468 (91.1)		
Yes	51 (9.9)	46 (8.9)		
Lung cancer or mesothelioma			/	1.000*
No	513 (99.8)	513 (99.8)		
Yes	1 (0.2)	1 (0.2)		

Note: "/" means Fisher exact probability method does not give chi-square values.

Abbreviation: PTB=pulmonary tuberculosis.

* Fisher exact probability method was used for statistics.

SUPPLEMENTARY TABLE S3. Comparison of pneumoconiosis-related symptoms between patients in two survey groups ($n=514$).

Symptoms	Group	Level	The first survey n (%)	Secondary follow-up survey n (%)	P
Cough	Control group	No	51 (9.9)	113 (22.0)	<0.001
		Mild	310 (60.3)	313 (60.9)	
		Moderate and severe	153 (29.8)	88 (17.1)	
	Lavage group	No	38 (7.4)	135 (26.3)	<0.001
		Mild	319 (62.1)	310 (60.3)	
		Moderate and severe	157 (30.5)	69 (13.4)	
Expectoration	Control group	No	102 (19.8)	166 (32.3)	<0.001
		Mild	280 (54.5)	270 (52.5)	
		Moderate and severe	132 (25.7)	78 (15.2)	
	Lavage group	No	60 (11.7)	181 (35.2)	<0.001
		Mild	323 (62.8)	260 (50.6)	
		Moderate and severe	131 (25.5)	73 (14.2)	
Chest tightness	Control group	No	64 (12.5)	164 (31.9)	<0.001
		Mild	295 (57.4)	258 (50.2)	
		Moderate and severe	155 (30.2)	92 (17.9)	
	Lavage group	No	48 (9.3)	157 (30.5)	<0.001
		Mild	310 (60.3)	261 (50.8)	
		Moderate and severe	156 (30.4)	96 (18.7)	
Chest pain	Control group	No	199 (38.7)	336 (65.4)	<0.001
		Mild	197 (38.3)	118 (23.0)	
		Moderate and severe	118 (23.0)	60 (11.7)	
	Lavage group	No	170 (33.1)	329 (64.0)	<0.001
		Mild	234 (45.5)	141 (27.4)	
		Moderate and severe	110 (21.4)	44 (8.6)	
Dyspnea	Control group	No	131 (25.5)	176 (34.2)	<0.001
		Mild	222 (43.2)	230 (44.7)	
		Moderate and severe	161 (31.3)	108 (21.0)	
	Lavage group	No	129 (25.1)	208 (40.5)	<0.001
		Mild	232 (45.1)	212 (41.2)	
		Moderate and severe	153 (29.8)	94 (18.3)	
Hemoptysis	Control group	No	460 (89.5)	486 (94.6)	0.002
		Yes	54 (10.5)	28 (5.4)	
	Lavage group	No	450 (87.5)	490 (95.3)	<0.001
		Yes	64 (12.5)	24 (4.7)	

SUPPLEMENTARY TABLE S4. Comparison of quality of life between the control group and the lavage group ($n=514$).

Quality of life	The first survey				Secondary follow-up survey			
	Control group	Lavage group	χ^2/t	P	Control group	Lavage group	χ^2/t	P
Mobility, n (%)			/	0.325*			4.801	0.091
No problems	302 (58.8)	322 (62.6)			365 (70.1)	388 (75.5)		
Moderate problems	206 (40.1)	189 (36.8)			140 (27.2)	123 (23.9)		
Extreme problems	6 (1.2)	3 (0.6)			9 (1.8)	3 (0.6)		
Self-care, n (%)			/	0.375*			/	0.198*
No problems	405 (78.8)	386 (75.1)			426 (82.9)	442 (86.0)		
Moderate problems	106 (20.6)	125 (24.3)			82 (16.0)	70 (13.6)		
Extreme problems	3 (0.6)	3 (0.6)			6 (1.2)	2 (0.4)		
Usual activities, n (%)			0.662	0.718			4.473	0.107
No problems	251 (48.8)	264 (51.4)			317 (61.7)	349 (67.9)		
Moderate problems	232 (45.1)	221 (43.0)			173 (33.7)	143 (27.8)		
Extreme problems	31 (6.0)	29 (5.6)			24 (4.7)	22 (4.3)		
Pain/discomfort, n (%)			4.488	0.106			5.483	0.063
No problems	118 (23.0)	147 (28.6)			233 (45.3)	234 (45.5)		
Moderate problems	352 (68.5)	330 (64.2)			255 (49.6)	268 (52.1)		
Extreme problems	44 (8.6)	37 (7.2)			26 (5.1)	12 (2.3)		
Anxiety/depression, n (%)			0.261	0.878			1.808	0.409
No problems	219 (42.6)	217 (42.2)			292 (56.8)	313 (60.9)		
Moderate problems	214 (41.6)	210 (40.9)			193 (37.5)	176 (34.2)		
Extreme problems	81 (15.8)	87 (16.9)			29 (5.6)	25 (4.9)		
Health status self-score ($\bar{x} \pm s$)	(59.11 \pm 17.3)	(59.0 \pm 17.2)	0.092	0.927	(68.7 \pm 15.8)	(69.3 \pm 16.3)	-0.644	0.520

Note: "/" means Fisher exact probability method does not give chi-square values.

Abbreviation: PTB=pulmonary tuberculosis.

* Fisher exact probability method was used for statistics.